Gesponsert
Biologics for severe asthma: the next frontier in India
For most asthma patients, inhaled steroids and bronchodilators work. But 5‑10% have severe, uncontrolled asthma despite maximum therapy. Enter biologics — monoclonal antibodies that block specific inflammatory pathways. The India respiratory drugs market forecast predicts that biologics will be a major growth driver in the next decade, as patents expire and local...
0 Kommentare 0 Anteile 42 Ansichten 0 Vorschau
Gesponsert
Gesponsert
Gesponsert